A. Kim

发表

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates

F. Balis, B. Widemann, C. McCully, 2012, Investigational New Drugs.

Cardiac changes in pediatric cancer survivors

R. McCarter, C. Spurney, L. Olivieri, 2020, Journal of Investigative Medicine.

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

Rachel A. Kudgus, B. Widemann, J. Reid, 2018, Pediatric blood & cancer.

Boiling histotripsy lesion characterization on a clinical magnetic resonance imaging-guided high intensity focused ultrasound system

Satya V. V. N. Kothapalli, David L. Woods, Bradford J. Wood, 2017, PloS one.

Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies

K. Reilly, D. Viskochil, B. Widemann, 2017, Sarcoma.

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

G. Giaccone, E. Kohn, D. Venzon, 2012, Clinical Cancer Research.

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis

C. Lázaro, G. Harris, M. Giovannini, 2018, American journal of medical genetics. Part A.

Chemotherapy and Multidisciplinary Approaches to Pediatric Sarcomas

J. Dome, H. Meany, A. Kim, 2017 .

Mechanical fractionation of tissues using microsecond-long HIFU pulses on a clinical MR-HIFU system

David L. Woods, B. Wood, A. Eranki, 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors

C. Brewer, R. Murphy, B. Widemann, 2015, Pediatric blood & cancer.

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

B. Crompton, C. Roberts, K. Stegmaier, 2016, JAMA oncology.

Sorafenib and sunitinib.

F. Balis, B. Widemann, A. Kim, 2009, The oncologist.

Technology and precision therapy delivery in childhood cancer.

A. Kim, Caitlin Tydings, AeRang Kim, 2019, Current opinion in pediatrics.

Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofibroma At Risk for Developing Tumor-Related Morbidity.

S. Steinberg, Michael Fisher, S. Paul, 2022, Neuro-oncology.

Cardiac changes in pediatric cancer survivors

R. McCarter, C. Spurney, L. Olivieri, 2019, Journal of Investigative Medicine.

Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors

A. Kim, Diana Bradford, 2015, Current Treatment Options in Oncology.

5th International Symposium on Focused Ultrasound

Matthew E. Downs, Gregory T. Clement, Chang Kyu Park, 2016, Journal of Therapeutic Ultrasound.

Phase 1 trial of lyso-thermosensitive liposomal doxorubicin (LTLD) and magnetic resonance guided high intensity focused ultrasound (MR-HIFU) for pediatric refractory solid tumors.

N. Borys, R. Kaplan, L. Warner, 2017 .

Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials

F. Balis, B. Widemann, E. Dombi, 2011, Clinical Cancer Research.

Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

P. Adamson, R. Murphy, F. Balis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The promise of signal transduction in genetically driven sarcomas of the nerve

C. Pratilas, A. Kim, AeRang Kim, 2018, Experimental Neurology.

The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors

J. Finlay, Lingyun Ji, R. Sposto, 2008, Pediatric blood & cancer.

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

A. Chen, D. Reinke, B. V. Van Tine, 2020, Sarcoma.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

D. Reinke, C. Meyer, L. Helman, 2019, Sarcoma.

Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Arie Perry, Karlyne M. Reilly, Brigitte Widemann, 2017, Human pathology.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

N. Ratner, B. Widemann, E. Dombi, 2016, The New England journal of medicine.

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

Seth M Steinberg, David J Venzon, D Wade Clapp, 2020, The New England journal of medicine.

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas

F. Balis, B. Widemann, E. Dombi, 2009, Neurology.

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

B. Widemann, N. Jayaprakash, M. Krailo, 2015, Pediatric blood & cancer.

Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.

D. Reinke, R. Maki, S. Schuetze, 2023, The oncologist.

Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

B. Widemann, E. Dombi, M. Fisher, 2014 .

Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience

Jonathan M Marron, B. Crompton, K. Janeway, 2016, Pediatric blood & cancer.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

S. Steinberg, B. Korf, N. Patronas, 2014, Neuro-oncology.

Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future

Karlyne M. Reilly, K. Reilly, D. Gutmann, 2017, Journal of the National Cancer Institute.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Karlyne M. Reilly, K. Reilly, D. Gutmann, 2017 .

Bone mineral density in children and young adults with neurofibromatosis type 1.

C. Stratakis, E. Bornstein, B. Widemann, 2012, Endocrine-related cancer.

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors

P. Hinds, C. Rodríguez-Galindo, W. London, 2021, Pediatric blood & cancer.

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas

P. Choyke, B. Korf, N. Muradyan, 2013, Pediatric blood & cancer.

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

S. Baruchel, P. Adamson, F. Balis, 2012, Clinical Cancer Research.

Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial.

S. Baruchel, P. Adamson, F. Balis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.

P. Adamson, F. Balis, B. Widemann, 2008, The oncologist.

Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors.

Jonathan M Marron, B. Crompton, A. Cronin, 2019, JCO precision oncology.

Pediatric oncology enters an era of precision medicine.

Yoon-Jae Cho, T. Laetsch, K. Janeway, 2017, Current problems in cancer.

Emerging hyperthermia applications for pediatric oncology.

P. Yarmolenko, Karun Sharma, A. Kim, 2020, Advanced drug delivery reviews.

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

D. Hawkins, B. Widemann, T. Zwerdling, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

D. Lindquist, N. Ratner, B. Widemann, 2012, Pediatric blood & cancer.

High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy

Christopher A. Lazarski, C. Moonen, B. Wood, 2019, Clinical Cancer Research.

SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).

S. Steinberg, D. Reinke, C. Meyer, 2016 .

Are Current Technical Exclusion Criteria for Clinical Trials of Magnetic Resonance-Guided High-Intensity Focused Ultrasound Too Restrictive?: Early Experiences at a Pediatric Hospital.

A. Eranki, P. Yarmolenko, Karun Sharma, 2020, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Technical aspects of osteoid osteoma ablation in children using MR-guided high intensity focussed ultrasound

A. Eranki, A. Partanen, P. Yarmolenko, 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Comparison of Noninvasive High‐Intensity Focused Ultrasound with Radiofrequency Ablation of Osteoid Osteoma

A. Eranki, A. Partanen, P. Yarmolenko, 2017, The Journal of pediatrics.

Multicenter study assessing tumor molecular profiles in advanced pediatric solid tumors.

B. Crompton, K. Stegmaier, M. Harris, 2014 .

Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

B. Widemann, J. Reid, D. Barkauskas, 2021 .

NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

S. Steinberg, S. Paul, Malcolm A. Smith, 2018, Neuro-Oncology.

SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

S. Steinberg, S. Paul, Malcolm A. Smith, 2016 .

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

S. Steinberg, S. Paul, D. Venzon, 2020, The New England journal of medicine.